Circulating miR-103 and miR-720 as novel serum biomarkers for patients with colorectal cancer

Ryoji Nonaka, Yuichiro Miyake, Taishi Hata, Yoshinori Kagawa, Takeshi Kato, Hideki Osawa, Junichi Nishimura, Masakazu Ikenaga, Kohei Murata, Mamoru Uemura, Daisuke Okuzaki, Ichiro Takemasa, Tsunekazu Mizushima, Hirofumi Yamamoto, Yuichiro Doki, Masaki Mori

Research output: Contribution to journalArticlepeer-review

37 Citations (Scopus)


Circulating microRNAs (miRNAs) have been reported as a biomarker for human malignancies, including colorectal cancer (CRC). The purpose of this study was to identify a novel biomarker for CRC through examination of serum miRNAs from the patients with CRC. Microarray analysis of miRNA expression was performed using paired pre- and post-operative serum from 10 CRC patients. miR-103 and miR-720 decreased significantly in the post-operative serum when compared to pre-operative serum. With an extended scale validation by qRT-PCR (quantitative real-time polymerase chain reaction) in 30 CRC patients, we confirmed that serum miR-103 and miR-720 decreased significantly after surgery (P=0.0004, and P=0.0274, respectively). Next, we examined serum miR-103 and miR-720 levels in 32 non-cancer patients and 84 CRC patients, and we found that expression of these two miRNAs was significantly higher in CRC patients than non-cancer patients. Furthermore, clinical and pathological survey indicated that high expression of miR-103 was significantly associated with histological differentiation grade, and lymphatic invasion and high expression of miR-720 was significantly associated with male gender and lymph node metastasis. Our data suggest that circulating miR-103 and miR-720 show potential as novel serum biomarkers for CRC.

Original languageEnglish
Pages (from-to)1097-1102
Number of pages6
JournalInternational journal of oncology
Issue number3
Publication statusPublished - Sept 1 2015
Externally publishedYes

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research


Dive into the research topics of 'Circulating miR-103 and miR-720 as novel serum biomarkers for patients with colorectal cancer'. Together they form a unique fingerprint.

Cite this